Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio to Participate in Upcoming Investor Conferences

April 18, 2023 | Last Trade: US$1.34 0.03 -2.19

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
Fireside Chat: Monday, April 24, 2023 at 9:30 am ET

H.C. Wainwright BioConnect Investor Conference
Fireside Chat: Tuesday, May 2, 2023 at 12:00 pm ET
Location: Nasdaq World Headquarters, New York, NY

The JMP Securities Life Sciences Conference
Fireside Chat: Tuesday, May 16, 2023 at 3:00 pm ET
Location: New York Hilton Midtown, New York, NY

A live webcast and archived replay of the fireside chats will be available on the investors section of our website, linked here: https://ir.vorbio.com/events-presentations/

About Vor Bio

Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Investors & Media
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$1.34
Daily Change:	-0.03 -2.19
Daily Volume:	1,141,995
Market Cap:	US$166.880M

January 08, 2025 Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors December 27, 2024 Vor Bio Announces $55.6 Million Private Placement December 09, 2024 Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design November 07, 2024 Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update September 05, 2024 New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies LOAD MORE NEWS

Featured Stock

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE